Plasma cell-rich rejection is a rare and poorly defined entity. Its treatment is not clearly defined and has universally poor prognosis. More data should be published from various transplant centers around the world to identify the treatment that has the best outcomes and to formulate treatment guidelines for these cases. It is a retrospective analysis of kidney biopsies form 2008 to 2018. Four hundred biopsied were screened and 55 were found to have features of rejection and among them, 13 had plasma cell-rich rejection. Data of treatment given and the graft survival outcomes in these cases were retrieved by medical records. One patient had complete recovery, three had graft loss and the remaining nine had permanent decline in glomerular filtration rate. Decrease in immunosuppression and presence of infection are risk factors for plasma cell-rich acute rejection (PCAR). It can be acute cell-mediated rejection (ACR)/antibody-mediated rejection (AMR)/ACR+AMR. Resistant rejection, ACR+AMR, C4d positivity, and severe interstitial inflammation are poor prognostic factors. Overzealous decrease in immunosuppression should not be done. Management of immunosuppression during infection is most critical for the development of PCAR. Bortezomib is emerging as a therapeutic modality for the treatment of PCAR.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4103/1319-2442.335451 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Castleman disease-type histopathological patterns of lymph nodes in patients with plasma cell neoplasia and POEMS syndrome.
Ann Diagn Pathol
February 2025
Pathology Department and Translational Hematopathology Lab, Hospital Universitario Marqués de Valdecilla/IDIVAL, UNICAN, Santander, Spain. Electronic address:
Plasma cell neoplasia and POEMS syndrome patients may present Castleman disease (CD)-type features in lymph nodes. Our aim was to better characterize the histopathological patterns found in plasma cell neoplasia associated CD and to improve the detection of clonal plasma cell populations in the lymph node biopsies of these patients. Lymph node and bone marrow samples from six cases with plasma cell neoplasia associated CD, including POEMS syndrome and multiple myeloma were analyzed.
View Article and Find Full Text PDFSerum and tissue biomarkers of plasma cell-rich rejection in liver transplant recipients.
Am J Transplant
October 2024
Division of Gastroenterology and Hepatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. Electronic address:
Article Synopsis
- There is a complex difference between autoimmune and alloimmune reactions in liver transplant patients, particularly involving an under-recognized form of graft rejection called plasma cell-rich rejection (PCRR).
- PCRR can lead to serious complications like advanced liver damage and transplant failure if not treated quickly, highlighting the need for effective detection methods.
- This study reviews potential blood and tissue biomarkers for diagnosing and monitoring PCRR in liver transplant recipients, as well as discusses related biomarkers from other medical conditions that might be applicable.
An Uncommon Finding of Plasma Cell Invasion of the Kidney in a Patient with Plasma Cell Dyscrasia: Should It be Considered a Myeloma Defining Event?
J Assoc Physicians India
October 2024
Professor and Head, Department of Nephrology, Indira Gandhi Institute of Medical Sciences, Patna, Bihar, India.
Article Synopsis
- Plasma cell infiltration in the kidney is a rare occurrence in patients with plasma cell dyscrasia, which can lead to rapid renal failure.
- A case study highlights a patient who experienced general weakness, anemia, and severe kidney issues, diagnosed through a kidney biopsy.
- The biopsy results showed aggressive plasma cell activity, indicating that such kidney infiltration may signal an underlying plasma cell disorder, potentially marking a significant progression in conditions like myeloma.
Successful Treatment of Plasma Cell-Rich Acute Rejection Using Bortezomib: A Case Report.
Case Rep Transplant
September 2024
Department of Pathology The State University of New York Upstate Medical University (SUNY Upstate Medical University), Syracuse, New York 13210, USA.
Plasma cell-rich acute rejection (PCAR), a relatively rare subtype of acute allograft rejection, is usually associated with a significantly lower treatment response rate and a higher graft failure rate. PCAR is characterized by the presence of more than 10% of plasma cells out of all graft infiltrating cells, with approximately 40%-60% of PCAR resulting in graft failure within a year. Currently, there is no gold standard for the effective treatment of PCAR.
View Article and Find Full Text PDFIgG4-Related Disease of Mastoid Presenting as Headache: A Case Report.
Cureus
July 2024
Radiodiagnosis, Dr. D.Y. Patil Medical College, Hospital and Research Centre, Pune, IND.
Article Synopsis
- IgG4-related disease (IgG4-RD) is a rare, multi-system inflammatory disorder marked by high levels of IgG4 and specific tissue damage, potentially affecting various organs, including the nervous system.
- A case study of a 53-year-old male showed he suffered from headaches and double vision due to complications like pachymeningitis and thrombosis related to IgG4-RD.
- Successful surgery and steroid treatment highlight the urgency of diagnosing and treating IgG4-RD to prevent serious organ damage, especially when conventional infections and cancers have been ruled out.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!